Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer
NCT02015169Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jul 2012
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in gastric cancer (GC), sponsored by Samsung Medical Center. Started Jul 2012; status: completed.
02
Drugs
lapatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02015169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015169.